Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020.

ABSTRACT:

Importance

Increasingly, cost-effectiveness analyses are being done to determine the value of rapidly increasing oncology drugs; however, this assumes that these analyses are unbiased.

Objective

To analyze the characteristics of cost-effectiveness studies and to determine characteristics associated with whether an oncology drug is found to be cost-effective.

Design, setting, and participants

This retrospective cross-sectional study included 254 cost-effectiveness analyses for 116 oncology drugs that were approved by the US Food and Drug Administration from 2015 to 2020.

Exposures

Each drug was analyzed for the incremental cost-effectiveness ratio per quality-adjusted life year, the funding of the study, the authors' conflict of interest, the threshold of willin

SUBMITTER: Haslam A 

PROVIDER: S-EPMC8603079 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature